[{"quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed126", "question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed126-001", "question": "A 3-day-old term neonate presents with progressive cyanosis unresponsive to supplemental oxygen. Echocardiography reveals d-transposition of the great arteries with intact ventricular septum and a restrictive patent foramen ovale. Prostaglandin E1 infusion is initiated but cyanosis persists with oxygen saturation of 55%. The infant is hemodynamically stable with adequate biventricular function. Which of the following is the most appropriate next step in management?", "options": ["Emergent arterial switch operation", "Balloon atrial septostomy", "Extracorporeal membrane oxygenation", "Inhaled nitric oxide therapy", "Atrial septectomy via median sternotomy"], "answer": "B", "answer_index": 1, "explanation": "In d-TGA with intact ventricular septum and restrictive atrial communication, balloon atrial septostomy (Rashkind procedure) is the urgent intervention to improve mixing at the atrial level. PGE1 maintains ductal patency but cannot improve atrial mixing when the foramen ovale is restrictive. Arterial switch is definitive but requires stabilization first. ECMO is reserved for refractory cases after septostomy. Surgical septectomy is more invasive and reserved for failed balloon septostomy.", "generator_model": "claude-opus-4-5-20251101", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "B", "model_outputs": "This patient has d-transposition of the great arteries (d-TGA) with an intact ventricular septum (IVS) and severe hypoxemia (oxygen saturation of 55%) despite prostaglandin E1 (PGE1) infusion. In d-TGA, the systemic and pulmonary circulations are arranged in parallel rather than in series. Survival depends on mixing of blood between the two circuits at the ductal (PDA), atrial (PFO/ASD), or ventricular (VSD) levels.\n\nIn this case, there is no VSD (intact ventricular septum). PGE1 maintains ductal patency, but effective mixing is often limited if the atrial communication is restrictive. Oxygenated blood returning from the lungs to the left atrium cannot cross adequately to the right side of the heart to be pumped to the body/aorta. This results in severe systemic hypoxemia and left atrial hypertension.\n\nThe most appropriate next step to stabilize the neonate is to improve interatrial mixing. This is classically achieved via a balloon atrial septostomy (Rashkind procedure). This procedure involves passing a balloon-tipped catheter across the foramen ovale into the left atrium, inflating it, and pulling it back forcefully across the septum to tear the valve of the foramen ovale, creating a non-restrictive atrial septal defect. This allows oxygenated blood to mix freely into the right atrium and ventricle, significantly improving systemic oxygen saturation. This stabilization allows for the definitive repair (Arterial Switch Operation) to be performed under more stable conditions shortly thereafter.\n\nWhile the *Arterial Switch Operation* (Option A) is the definitive treatment, performing major cardiac surgery on a severely hypoxemic, unstabilized neonate carries higher risks compared to stabilizing them first with a septostomy. *Inhaled nitric oxide* (Option D) is generally not helpful and can be harmful in this specific setting (d-TGA with restrictive PFO) because it increases pulmonary blood flow and left atrial return, potentially worsening left atrial hypertension and pulmonary edema if the PFO is restrictive. *ECMO* (Option C) is reserved for patients who cannot be stabilized by other means.\n\nThe answer is (B)"}, {"quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed126", "question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed126-002", "question": "A 58-year-old woman with longstanding rheumatoid arthritis on methotrexate and adalimumab presents with 6 weeks of progressive dyspnea and dry cough. HRCT shows diffuse ground-glass opacities with areas of consolidation in a peribronchovascular distribution. Bronchoalveolar lavage reveals 45% lymphocytes with CD4/CD8 ratio of 0.5. Methotrexate pneumonitis is suspected. Which histopathologic pattern is most commonly associated with methotrexate-induced lung toxicity?", "options": ["Usual interstitial pneumonia", "Diffuse alveolar damage", "Hypersensitivity pneumonitis pattern", "Organizing pneumonia", "Pulmonary alveolar proteinosis"], "answer": "C", "answer_index": 2, "explanation": "Methotrexate-induced lung toxicity most commonly manifests as a hypersensitivity pneumonitis pattern, characterized by lymphocytic alveolitis with low CD4/CD8 ratio, granulomas, and interstitial inflammation. The BAL findings of elevated lymphocytes with inverted CD4/CD8 ratio support this diagnosis. While organizing pneumonia and diffuse alveolar damage can occur, hypersensitivity pneumonitis is the predominant pattern. UIP pattern is more characteristic of RA-ILD itself rather than drug toxicity.", "generator_model": "claude-opus-4-5-20251101", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "C", "model_outputs": "Methotrexate-induced lung toxicity (methotrexate pneumonitis) is considered a drug-induced hypersensitivity reaction. The classic clinical presentation includes subacute onset of dyspnea, non-productive cough, and fever.\n\n1.  Bronchoalveolar Lavage (BAL): Typically demonstrates a lymphocytic alveolitis. While the CD4/CD8 ratio is classically described as increased (helper T-cell predominant) in some texts to distinguish it from other forms of hypersensitivity pneumonitis (which often have a low ratio), variable ratios (including low ratios reversed like the 0.5 in this vignette) are well-documented in methotrexate pneumonitis. The key finding is the significant lymphocytosis.\n\n2.  Histopathology: The most characteristic and common histopathologic finding is cellular interstitial pneumonia with mononuclear cell infiltration (lymphocytes, plasma cells, macrophages). A hallmark feature that helps distinguish it from other drug-induced interstitial lung diseases is the presence of non-necrotizing, poorly formed granulomas and multinucleated giant cells.\n    *   This constellation of findings (cellular interstitial pneumonitis + granulomas) defines a hypersensitivity pneumonitis pattern.\n    *   While areas of Organizing Pneumonia (OP) and Diffuse Alveolar Damage (DAD) can be seen, the hypersensitivity pattern is the most classic and distinct association.\n\n3.  Ruling out other options:\n    *   *Usual interstitial pneumonia (A)* is the pattern associated with idiopathic pulmonary fibrosis and is a common pattern in rheumatoid arthritis-associated ILD (RA-ILD), but it is not the classic pattern of acute/subacute methotrexate toxicity.\n    *   *Diffuse alveolar damage (B)* corresponds to acute respiratory distress syndrome (ARDS) and is seen in severe, life-threatening cases but is less common than the hypersensitivity pattern.\n    *   *Organizing pneumonia (D)* (characterized by Masson bodies) can occur but is less specific than the granulomatous inflammation characteristic of methotrexate's hypersensitivity mechanism. The vignette's mention of peribronchovascular consolidation is consistent with OP, which can be a component of the hypersensitivity reaction, but the most encompassing answer for the general pathology of MTX lung is the HP pattern.\n    *   *Pulmonary alveolar proteinosis (E)* is not associated with methotrexate.\n\nTherefore, the histopathologic pattern most commonly associated with methotrexate-induced lung toxicity is the hypersensitivity pneumonitis pattern.\n\nThe answer is (C)"}, {"quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed126", "question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed126-003", "question": "A 32-year-old woman at 28 weeks gestation presents with severe preeclampsia. Despite magnesium sulfate and labetalol, she develops pulmonary edema requiring intubation. Echocardiography shows preserved ejection fraction of 65% with grade III diastolic dysfunction and elevated E/e' ratio of 18. Central venous pressure is 4 mmHg. Which pathophysiologic mechanism best explains her pulmonary edema?", "options": ["Systolic heart failure from peripartum cardiomyopathy", "Increased pulmonary capillary permeability from endothelial dysfunction", "Volume overload from iatrogenic fluid administration", "Diastolic dysfunction from acute afterload mismatch", "Mitral regurgitation from papillary muscle dysfunction"], "answer": "D", "answer_index": 3, "explanation": "Severe preeclampsia causes acute hypertensive crisis leading to afterload mismatch. The preserved EF with grade III diastolic dysfunction and elevated E/e' indicates heart failure with preserved ejection fraction due to impaired ventricular relaxation from acute pressure overload. The low CVP argues against volume overload. While endothelial dysfunction occurs in preeclampsia, the echocardiographic findings point to diastolic dysfunction as the primary mechanism. Peripartum cardiomyopathy would show reduced systolic function.", "generator_model": "claude-opus-4-5-20251101", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "D", "model_outputs": "This patient presents with pulmonary edema in the setting of severe preeclampsia. The key to answering this question lies in interpreting the echocardiographic and hemodynamic data provided.\n\n1.  Echocardiography Findings: The patient has a preserved ejection fraction (EF) of 65%, which rules out systolic heart failure (Option A). However, she has Grade III diastolic dysfunction and an elevated E/e' ratio of 18. The E/e' ratio is a non-invasive marker of left ventricular filling pressures; a ratio > 15 indicates elevated left ventricular end-diastolic pressure (LVEDP) or pulmonary capillary wedge pressure (PCWP).\n2.  Central Venous Pressure (CVP): The CVP is 4 mmHg, which is low-to-normal. This argues against gross systemic volume overload (Option C) as the primary cause, where one would expect elevated right-sided filling pressures as well.\n3.  Pathophysiology: Preeclampsia is a state of high systemic vascular resistance (SVR) due to profound vasoconstriction. This presents a sudden, massive increase in afterload to the left ventricle. In patients with underlying predisposition or severe disease, the left ventricle cannot relax sufficiently against this high afterload (diastolic dysfunction). Consequently, LVEDP rises, transmitting pressure back to the pulmonary circulation and causing hydrostatic pulmonary edema. This phenomenon is known as \"afterload mismatch.\"\n4.  Other Options:\n    *   Option B (Permeability): While endothelial dysfunction and capillary leak are hallmarks of preeclampsia, the specific echocardiographic findings (elevated E/e') indicate a hemodynamic (cardiac) cause for the edema (hydrostatic pressure), making diastolic dysfunction the *best* explanation for the clinical picture described.\n    *   Option A (Peripartum CM): See above; EF is preserved.\n    *   Option C (Volume Overload): CVP is low, making this less likely than pump failure.\n    *   Option E (Mitral Regurgitation): There is no data provided (e.g., murmur, color flow Doppler) to support acute MR.\n\nTherefore, the pulmonary edema is driven by the stiff left ventricle's inability to handle the high afterload (preeclampsia), resulting in elevated pulmonary venous pressures despite normal systolic function and lack of systemic volume overload.\n\nThe answer is (D)"}, {"quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed126", "question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed126-004", "question": "A 67-year-old man with ischemic cardiomyopathy (EF 25%) and cardiac resynchronization therapy-defibrillator presents after appropriate ICD shock for ventricular tachycardia. He is on maximally tolerated guideline-directed medical therapy including sacubitril-valsartan, carvedilol, spironolactone, and dapagliflozin. Electrophysiology study reveals scar-related reentrant VT from the inferolateral left ventricle. Catheter ablation is performed. Three months later, he has recurrent VT storm despite amiodarone. Which additional pharmacologic therapy has demonstrated mortality benefit in this specific population?", "options": ["Mexiletine", "Sotalol", "Ranolazine", "Quinidine", "Dofetilide"], "answer": "A", "answer_index": 0, "explanation": "Mexiletine, a class IB sodium channel blocker, when added to amiodarone in patients with recurrent VT despite amiodarone monotherapy, has shown reduction in VT recurrence and ICD shocks. The MEXICA trial demonstrated this combination's efficacy. Sotalol and dofetilide have proarrhythmic risks in low EF patients. Quinidine has significant toxicity and limited modern data. Ranolazine has some antiarrhythmic properties but lacks robust evidence in scar-related VT. Mexiletine's synergistic sodium channel blockade with amiodarone provides additional substrate modification.", "generator_model": "claude-opus-4-5-20251101", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "A", "model_outputs": "The patient is an Ischemic Cardiomyopathy patient with a CRT-D who presents with recurrent VT storm despite optimal medical therapy (GDMT) and Amiodarone, and after Catheter Ablation has failed (or recurrence occurred post-ablation).\n\nThe clinical question asks for an additional pharmacologic therapy that has demonstrated mortality benefit in this specific population.\n\nLet's analyze the options:\n*   A. Mexiletine: This Class Ib antiarrhythmic is the standard \"add-on\" therapy to Amiodarone for refractory VT storm (Class IIa recommendation). While the VANISH trial (comparing Ablation vs. Escalated Therapy [Amio + Mexiletine]) showed ablation was superior, the drug arm established Mexiletine + Amiodarone as the standard pharmacologic comparator. Observational studies and meta-analyses in refractory VT storm suggest that successful suppression of the arrhythmia (often achieved with this combination) is associated with improved survival compared to non-suppression. However, large RCTs demonstrating intrinsic mortality benefit (vs placebo) are lacking; it is rather the \"standard of care\" for suppression which saves lives in the context of storm.\n*   B. Sotalol: In the ESVEM trial, Sotalol showed improved survival compared to Class I antiarrhythmics (like Mexiletine, Quinidine, etc.) in patients with frequent ventricular arrhythmias. However, Sotalol is generally considered inferior to Amiodarone for suppression of VT and carries a risk of Torsades (QT prolongation) and worsening heart failure. Adding Sotalol to Amiodarone is typically contraindicated due to QT prolongation and beta-blocker adjustments.\n*   C. Ranolazine: The RAID trial evaluated Ranolazine in high-risk ICD patients. While it significantly reduced the burden of VT/VF and ICD therapies, it did not demonstrate a significant reduction in the primary composite endpoint of death or VT/VF, nor did it reduce mortality alone.\n*   D. Quinidine: Class Ia. While effective in niche cases (Brugada, Short QT, and sometimes refractory ischemic storm purely for suppression as \"salvage\"), historical meta-analyses (e.g., Morganroth) suggest Class Ia agents may increase mortality in ischemic heart disease. It is not the standard answer for \"demonstrated mortality benefit\".\n*   E. Dofetilide: The DIAMOND trials showed Dofetilide is safe (neutral) regarding mortality in heart failure/MI but did not demonstrate a mortality *benefit*. It reduced rehospitalization.\n\nRe-evaluation of the \"Mortality Benefit\" claim:\nMost sources teach that no antiarrhythmic drug (except Beta-Blockers) has a demonstrated mortality benefit in ischemic cardiomyopathy. However, in the specific setting of Electrical Storm refractory to standard therapy, guidelines and clinical outcomes data support the use of Mexiletine as an adjunct to Amiodarone.\nReviewing recent literature or specific \"Board Review\" facts: There is often a reference to the ESVEM trial where Sotalol was better than standard Class I agents, but this doesn't fit the \"Add-on to Amio\" scenario.\nThere is, however, a line of evidence regarding Quinidine in *refractory* patients where it might save lives as salvage, but it is not the main teaching point.\n\nHowever, carefully considering the exact phrasing of board questions:\nSometimes the question refers to Lipid lowering or Beta Blockade (Carvedilol), but the patient is already on them.\nIf forced to choose the antiarrhythmic intended:\nClinically, Mexiletine is the correct next step.\nIs there a specific study claiming mortality benefit for Mexiletine?\nSome retrospective analyses (e.g., Gao et al, *J Cardiovasc Electrophysiol* 2013) suggest that Mexiletine combined with Amiodarone improved survival free of appropriate shocks (which are a proxy for death risk/mortality). In the absence of a better option, and given it is the standard guideline-directed add-on, Mexiletine is the best answer. (Some sources might argue Quinidine for salvage, but Mexiletine is the routine answer).\n\nMost importantly, in the VANISH trial context, the \"Escalated Medical Therapy\" arm (Amio+Mexiletine) was the comparator. While it lost to ablation, it is the standard medical care for those who fail or cannot have ablation.\nGiven the patient has *failed* ablation, the standard of care is Mexiletine (A). The prompt's \"demonstrated mortality benefit\" likely refers to the benefit of controlling the storm.\n\nThe answer is (A)"}, {"quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed126", "question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed126-005", "question": "A 6-year-old boy presents with recurrent episodes of fever, cervical lymphadenopathy, aphthous stomatitis, and pharyngitis occurring every 4-6 weeks since age 2. Episodes resolve spontaneously within 5 days. Between episodes, he is completely well with normal growth. Laboratory studies during an episode show elevated CRP and ESR with normal complete blood count. Genetic testing for FMF, TRAPS, and HIDS mutations is negative. Which treatment has the highest likelihood of inducing complete remission?", "options": ["Colchicine prophylaxis", "Anakinra during episodes", "Single-dose corticosteroid at episode onset", "Tonsillectomy with or without adenoidectomy", "Cimetidine prophylaxis"], "answer": "D", "answer_index": 3, "explanation": "PFAPA syndrome (Periodic Fever, Aphthous stomatitis, Pharyngitis, Adenitis) is the most common periodic fever syndrome in children. While corticosteroids abort individual episodes, they may shorten the interval between attacks. Tonsillectomy (with or without adenoidectomy) achieves complete resolution in 63-95% of patients and is considered curative. Colchicine and cimetidine have variable efficacy for prophylaxis. Anakinra is reserved for refractory cases. The classic presentation with negative genetic testing and stereotypical episodes strongly supports PFAPA, where tonsillectomy offers the best chance of definitive cure.", "generator_model": "claude-opus-4-5-20251101", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "D", "model_outputs": "Based on the clinical presentation, the patient has PFAPA syndrome (Periodic Fever, Aphthous stomatitis, Pharyngitis, and Adenitis). The diagnostic criteria met include:\n*   Regularly recurring fevers with an early age of onset (<5 years).\n*   Constitutional symptoms in the absence of upper respiratory infection characterized by at least one of the following: aphthous stomatitis, cervical lymphadenitis, or pharyngitis.\n*   Exclusion of cyclic neutropenia.\n*   Asymptomatic interval between episodes.\n*   Normal growth and development.\n\nHere is an analysis of the treatment options regarding the likelihood of inducing complete remission (cessation of episodes):\n\n*   A. Colchicine prophylaxis: While effective for Familial Mediterranean Fever (FMF), its efficacy in PFAPA is variable and generally lower. It may reduce frequency but is less likely to induce complete remission compared to surgery.\n*   B. Anakinra: IL-1 blockade can be effective in some autoinflammatory syndromes and refractory PFAPA, but it is not the standard first-line definitive treatment for PFAPA, and data regarding long-term remission is less robust than for tonsillectomy.\n*   C. Single-dose corticosteroid: This is highly effective for aborting an individual episode (symptoms resolve rapidly). However, it does not induce remission of the syndrome; conversely, it often shortens the interval between febrile episodes.\n*   D. Tonsillectomy with or without adenoidectomy: Clinical studies and randomized controlled trials have demonstrated that tonsillectomy is highly effective for PFAPA, resulting in immediate and complete resolution (remission) of symptoms in a vast majority of patients (efficacy rates typically cited between 60% to >90%). It is considered the most effective intervention for curing the condition.\n*   E. Cimetidine prophylaxis: This has been used with modest success (approx. 30% remission rate), but it is significantly less effective than tonsillectomy.\n\nTherefore, surgical intervention has the highest likelihood of ensuring the patient has no further episodes.\n\nThe answer is (D)"}, {"quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed126", "question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed126-006", "question": "A 45-year-old woman with systemic lupus erythematosus develops acute kidney injury with serum creatinine rising from 1.0 to 3.8 mg/dL over 2 weeks. Urinalysis shows 3+ protein, numerous RBC casts, and dysmorphic red cells. Complement levels are low. Kidney biopsy reveals diffuse proliferative glomerulonephritis (Class IV-G) with 40% cellular crescents, wire loop lesions, and activity index of 14/24 with chronicity index of 2/12. Anti-dsDNA antibody titer is markedly elevated. Which induction regimen has demonstrated superior renal response rates in this clinical scenario?", "options": ["Mycophenolate mofetil plus glucocorticoids", "Cyclophosphamide (Euro-Lupus protocol) plus glucocorticoids", "Voclosporin plus mycophenolate mofetil plus glucocorticoids", "Rituximab plus mycophenolate mofetil plus glucocorticoids", "Belimumab plus cyclophosphamide plus glucocorticoids"], "answer": "C", "answer_index": 2, "explanation": "The AURORA trial demonstrated that voclosporin added to mycophenolate mofetil and low-dose glucocorticoids achieved significantly higher complete renal response rates (41% vs 23%) at 52 weeks compared to MMF and glucocorticoids alone in active lupus nephritis. This triple therapy showed benefit across Class III, IV, and V lupus nephritis. While MMF and cyclophosphamide are established induction agents, the addition of voclosporin (a novel calcineurin inhibitor) provides superior efficacy. Rituximab and belimumab combinations lack the same level of evidence for superior renal response in this setting.", "generator_model": "claude-opus-4-5-20251101", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "E", "model_outputs": "The clinical scenario describes a patient with severe, active, proliferative lupus nephritis (Class IV-G) characterized by a high activity index (14/24), cellular crescents (40%), and significant acute kidney injury (creatinine 3.8 mg/dL).\n\n1.  Standard of Care: For severe lupus nephritis with loss of kidney function (high creatinine) and cellular crescents, Cyclophosphamide (CYC) plus glucocorticoids is historically the preferred induction backbone due to its potency and reliability compared to Mycophenolate Mofetil (MMF). MMF was shown to be non-inferior (equivalent), not superior, to CYC in the ALMS trial, and relies on enterohepatic recycling which can be unreliable in uremic/sick patients. Calcineurin inhibitors (CNIs) like Voclosporin are typically contraindicated or used with extreme caution in patients with severe acute kidney injury (eGFR < 45 mL/min) due to the risk of acute hemodynamic worsening of kidney function.\n2.  Add-on Therapies: Recent trials have evaluated adding biological agents or CNIs to standard therapy (MMF or CYC) to improve response rates.\n    *   Voclosporin (Option C): The AURORA trial showed that adding Voclosporin to MMF + steroids resulted in superior renal response rates compared to MMF + steroids alone. However, the trial excluded patients with eGFR < 45 mL/min/1.73 m² (unless acute and reviewed), and the label does not recommend initiation at this level of renal dysfunction (Cr 3.8 mg/dL).\n    *   Rituximab (Option D): The LUNAR trial (Rituximab + MMF vs MMF) failed to meet its primary endpoint of superior renal response. It is used off-label for refractory cases but has not demonstrated superiority in a registration induction trial.\n    *   Belimumab (Option E): The BLISS-LN trial compared Belimumab + Standard of Care (MMF or CYC) versus Placebo + Standard of Care. The trial demonstrated that the addition of Belimumab yielded superior primary efficacy renal response rates compared to standard therapy alone. The benefit was observed in subgroups treated with both MMF and CYC. Given the severity of this patient's disease (crescents, AKI), a Cyclophosphamide backbone is clinically indicated. The combination of Belimumab plus Cyclophosphamide plus glucocorticoids represents an evidence-based regimen that uses the appropriate backbone for severe disease and includes an add-on agent proven to provide superior response rates compared to standard therapy alone. Additionally, patients with high disease activity (high anti-dsDNA, low complement) were shown to derive significant benefit.\n\nTherefore, Option E is the best answer as it combines the clinically preferred backbone for severe crescentic/AKI lupus nephritis (Cyclophosphamide) with an agent (Belimumab) that has demonstrated superior renal response rates when added to standard therapy in a clinical trial setting, without the contraindication profile of CNIs in severe renal failure.\n\nThe answer is (E)"}, {"quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed126", "question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed126-007", "question": "A 72-year-old man is admitted to the ICU with septic shock from pneumonia. Despite adequate fluid resuscitation and norepinephrine at 0.5 mcg/kg/min, MAP remains 58 mmHg. Echocardiography shows hyperdynamic left ventricle with EF 75%, small LV cavity, and IVC diameter of 0.8 cm with >50% respiratory variation. Lactate is 6.2 mmol/L. Which vasopressor strategy is most appropriate?", "options": ["Add vasopressin 0.03 units/min", "Add epinephrine infusion", "Add phenylephrine infusion", "Add angiotensin II infusion", "Increase norepinephrine to maximum dose before adding second agent"], "answer": "A", "answer_index": 0, "explanation": "Current sepsis guidelines recommend adding vasopressin (up to 0.03 units/min) as the second-line vasopressor when norepinephrine fails to achieve target MAP, typically when norepinephrine exceeds 0.25-0.5 mcg/kg/min. Vasopressin acts via V1 receptors independent of catecholamine pathways, which may be downregulated in sepsis. The VASST trial showed potential mortality benefit in less severe septic shock. The echocardiographic findings suggest adequate volume status (small IVC with variation indicates fluid responsiveness is exhausted). Angiotensin II is reserved for refractory vasodilatory shock after multiple agents. Phenylephrine may reduce cardiac output.", "generator_model": "claude-opus-4-5-20251101", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "A", "model_outputs": "This patient presents with septic shock and refractory hypotension (MAP 58 mmHg) despite a high dose of norepinephrine (0.5 mcg/kg/min). The guideline-directed medical therapy for septic shock that is refractory to norepinephrine is the addition of a second vasopressor.\n\nAccording to the Surviving Sepsis Campaign Guidelines (2021):\n- Norepinephrine is the first-line vasopressor.\n- For patients on norepinephrine with inadequate MAP guidelines suggest adding vasopressin (up to 0.03 units/min) rather than escalating the norepinephrine dose further. This is typically considered when the norepinephrine dose is in the range of 0.25–0.5 mcg/kg/min.\n\nLooking at the specific physiology provided by the echocardiogram:\n- The LV is hyperdynamic (EF 75%) with a small cavity. This indicates a high contractile state and susceptibility to dynamic left ventricular outflow tract (LVOT) obstruction if inotropy is further increased or if afterload remains too low.\n- The IVC is small and collapsible, suggesting volume responsiveness, but the question asks for a vasopressor strategy (assuming fluid status is being addressed or the \"adequate fluid resuscitation\" in the prompt implies the clinical team has limited further fluids due to other factors).\n\nAnalysis of Options:\n- A. Add vasopressin 0.03 units/min: This is the correct guideline-supported step. Vasopressin increases systemic vascular resistance (SVR) without increasing myocardial contractility or heart rate, which is ideal in a hyperdynamic heart where avoiding dynamic obstruction is important. It also spares the use of catecholamines.\n- B. Add epinephrine infusion: Epinephrine has potent beta-1 agonist activity, which increases inotropy and heart rate. In a patient with a small, hyperdynamic ventricle, this could precipitate or worsen dynamic LVOT obstruction (suction effect) and worsen hypotension. It also increases myocardial oxygen demand and lactate production.\n- C. Add phenylephrine infusion: While phenylephrine is a pure alpha agonist and could be used, it is generally not recommended as a second-line agent in septic shock unless there are significant tachyarrhythmias or high cardiac output with hypotension where norepinephrine is failing. Vasopressin is the superior evidence-based choice for sparing norepinephrine.\n- D. Add angiotensin II infusion: This is a newer agent typically reserved for vasodilatory shock refractory to high-dose catecholamines and vasopressin (third-line).\n- E. Increase norepinephrine: The patient is already on a high dose (0.5 mcg/kg/min). Further increases carry a high risk of adverse events (ischemia, arrhythmia) with diminishing returns on blood pressure. Adding a second agent with a different mechanism of action is preferred.\n\nThus, adding vasopressin is the most appropriate next step both by general sepsis guidelines and specifically suited to the patient's hyperdynamic physiology.\n\nThe answer is (A)"}, {"quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed126", "question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed126-008", "question": "A 29-year-old primigravida at 34 weeks gestation presents with sudden-onset severe headache and right-sided weakness. Blood pressure is 178/112 mmHg. CT head shows left parietal intracerebral hemorrhage with surrounding edema. MRV demonstrates absence of flow in the superior sagittal sinus and left transverse sinus consistent with cerebral venous thrombosis. Platelet count is 82,000/μL, LDH is elevated, and peripheral smear shows schistocytes. Which is the most appropriate immediate management?", "options": ["Emergent cesarean delivery followed by therapeutic anticoagulation", "Therapeutic anticoagulation with unfractionated heparin", "Platelet transfusion followed by decompressive craniectomy", "Plasma exchange followed by anticoagulation", "Magnesium sulfate and antihypertensives with delayed anticoagulation"], "answer": "A", "answer_index": 0, "explanation": "This patient has cerebral venous thrombosis complicated by hemorrhagic transformation in the setting of HELLP syndrome (hemolysis, elevated liver enzymes, low platelets) evidenced by thrombocytopenia, elevated LDH, and schistocytes. The definitive treatment for HELLP is delivery. While anticoagulation is standard for CVT even with hemorrhage, the underlying HELLP syndrome will not resolve without delivery and may worsen, increasing bleeding risk. Emergent cesarean delivery addresses the root cause, after which therapeutic anticoagulation can be safely initiated. Plasma exchange is for TTP, not HELLP. Delaying anticoagulation without addressing HELLP is inappropriate.", "generator_model": "claude-opus-4-5-20251101", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "A", "model_outputs": "The clinical presentation is consistent with HELLP syndrome (Hemolysis, Elevated Liver enzymes, Low Platelets) complicated by Cerebral Venous Thrombosis (CVT) and Intracerebral Hemorrhage (ICH).\n\n1.  Diagnosis: The patient has severe hypertension (178/112 mmHg) and thrombocytopenia (82,000/μL) in the third trimester (34 weeks), which strongly points to severe preeclampsia/HELLP syndrome. The presence of schistocytes indicates microangiopathic hemolytic anemia, a key feature of HELLP. This distinguishes the condition from Thrombotic Thrombocytopenic Purpura (TTP), which typically presents without severe hypertension (or less prominent hypertension) and would be treated with plasma exchange (making Option D incorrect).\n2.  Neurological Complication: MRV confirms CVT, and CT shows ICH. Pregnancy and preeclampsia are hypercoagulable states increasing the risk of CVT.\n3.  Management of CVT with ICH: The standard of care for CVT is therapeutic anticoagulation (LMWH or UFH) to prevent thrombus propagation and facilitate venous drainage, even in the presence of hemorrhagic transformation (the hemorrhage is usually secondary to venous congestion).\n4.  Obstetric Management: The definitive treatment for HELLP syndrome at 34 weeks gestation is delivery. Given the patient's neurological status (ICH, increased intracranial pressure risk) and the need for rapid stabilization of the maternal condition, emergent cesarean delivery is indicated to avoid the Valsalva maneuver associated with the second stage of labor, which could worsen intracranial pressure.\n5.  Sequence: Immediate anticoagulation with UFH (Option B) addresses the clot but fails to treat the underlying HELLP syndrome via delivery and might complicate surgical hemostasis if started immediately before an emergent section. Platelet transfusion (Option C) is generally not indicated for a count of 82,000/μL (threshold for C-section is typically 50,000/μL) and does not address the root causes. Decompressive craniectomy is reserved for cases with significant midline shift or impending herniation, not described here.\n\nTherefore, the best approach is to perform an emergent cesarean delivery to cure the HELLP syndrome and protect the fetus/mother, followed by therapeutic anticoagulation to treat the CVT.\n\nThe answer is (A)"}, {"quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed126", "question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed126-009", "question": "A 14-year-old girl presents with 3 months of progressive fatigue, arthralgia, and facial rash. Laboratory evaluation reveals ANA 1:1280 (homogeneous pattern), anti-dsDNA positive, anti-Smith positive, C3 45 mg/dL (normal 90-180), C4 6 mg/dL (normal 10-40), and anti-C1q antibodies positive. Urinalysis shows 2+ protein and 10-15 RBCs/hpf. She is diagnosed with juvenile-onset systemic lupus erythematosus. The presence of anti-C1q antibodies in this patient most specifically predicts which disease manifestation?", "options": ["Neuropsychiatric lupus", "Proliferative lupus nephritis", "Antiphospholipid syndrome", "Lupus pneumonitis", "Autoimmune hemolytic anemia"], "answer": "B", "answer_index": 1, "explanation": "Anti-C1q antibodies have the highest specificity for lupus nephritis, particularly proliferative forms (Class III/IV). Studies demonstrate that anti-C1q antibodies have a negative predictive value approaching 100% for active renal disease-their absence essentially excludes active nephritis. The combination of anti-C1q with anti-dsDNA antibodies and low complement strongly predicts proliferative nephritis. While anti-C1q can be seen in hypocomplementemic urticarial vasculitis, in SLE context, they specifically correlate with renal involvement. Anti-ribosomal P antibodies are more associated with neuropsychiatric lupus.", "generator_model": "claude-opus-4-5-20251101", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "B", "model_outputs": "Here is the step-by-step breakdown of the reasoning:\n\n1.  Patient Evaluation: The patient is a 14-year-old female with classic signs of Systemic Lupus Erythematosus (SLE), including malar rash, arthralgia, fatigue, and specific serology (ANA, anti-dsDNA, anti-Smith). She also has evidence of active renal involvement (proteinuria, hematuria) and complement consumption (low C3 and C4).\n\n2.  Specific Antibody Analysis: The question focuses on the clinical significance of anti-C1q antibodies. C1q is the first subcomponent of the C1 complex of the classical pathway of complement activation.\n\n3.  Clinical Associations of Anti-C1q:\n    *   Anti-C1q antibodies are highly prevalent in patients with active SLE, particularly those with renal involvement.\n    *   There is a strong, well-established correlation between the presence and titer of anti-C1q antibodies and lupus nephritis (specifically active proliferative lupus nephritis).\n    *   The mechanism involves the deposition of immune complexes containing C1q in the glomeruli, activating the complement cascade and causing inflammation.\n    *   The absence of anti-C1q antibodies has a high negative predictive value for active lupus nephritis; conversely, their presence (especially with concurrent high anti-dsDNA and low complement) is a strong predictor of renal flares and proliferative histology.\n\n4.  Evaluating Distractors:\n    *   *Neuropsychiatric lupus* (Option A) is more commonly associated with anti-ribosomal P antibodies or antiphospholipid antibodies.\n    *   *Antiphospholipid syndrome* (Option C) is defined by lupus anticoagulant, anti-cardiolipin, or anti-beta-2 glycoprotein I antibodies.\n    *   *Lupus pneumonitis* (Option D) and *Autoimmune hemolytic anemia* (Option E) do not have anti-C1q as their primary specific predictor compared to nephritis.\n\n5.  Conclusion: The strongest and most clinically utilized association for anti-C1q antibodies in SLE is with active proliferative lupus nephritis.\n\nThe answer is (B)"}, {"quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed126", "question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed126-010", "question": "A 52-year-old man with no prior cardiac history presents with acute anterior STEMI. Primary PCI reveals 100% occlusion of the proximal LAD with TIMI 0 flow. After successful stenting with TIMI 3 flow restoration, he develops cardiogenic shock with blood pressure 78/52 mmHg, heart rate 112 bpm, and cardiac index 1.6 L/min/m². Echocardiography shows akinesis of the anterior wall, apex, and septum with EF 20%. He is started on norepinephrine and dobutamine. Despite escalating support, he remains in refractory shock. Which mechanical circulatory support device provides the greatest degree of left ventricular unloading?", "options": ["Intra-aortic balloon pump", "Impella CP", "TandemHeart", "Veno-arterial ECMO", "Impella 5.5"], "answer": "E", "answer_index": 4, "explanation": "Impella 5.5 provides up to 5.5 L/min of forward flow and the greatest degree of LV unloading among the options by actively aspirating blood from the LV and ejecting it into the ascending aorta. This reduces LV end-diastolic pressure, wall stress, and myocardial oxygen demand while maintaining systemic perfusion. VA-ECMO provides excellent systemic support but increases LV afterload and may worsen pulmonary edema without LV venting. TandemHeart provides good support but requires transseptal puncture. Impella CP provides only 3-4 L/min. IABP provides modest afterload reduction with minimal flow augmentation (0.5 L/min).", "generator_model": "claude-opus-4-5-20251101", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "E", "model_outputs": "This question addresses the hemodynamic effects of various mechanical circulatory support (MCS) devices, specifically regarding their impact on left ventricular (LV) unloading (reduction of LV wall stress and myocardial oxygen consumption).\n\n1.  A. Intra-aortic balloon pump (IABP): The IABP functions by counterpulsation. It inflates during diastole to augment coronary perfusion and deflates during systole to reduce afterload. While it provides a modest reduction in afterload and LV wall stress, the hemodynamic support (0.5–1.0 L/min augmentation) and degree of unloading are limited compared to active flow pumps.\n2.  D. Veno-arterial ECMO (VA-ECMO): VA-ECMO provides robust systemic perfusion and oxygenation by bypassing the heart and lungs. However, because it pumps blood retrograde into the aorta, it significantly increases LV afterload (arterial pressure). In a failing heart that cannot eject against this increased resistance, this leads to LV distension, increased wall stress, and increased myocardial oxygen demand. Therefore, VA-ECMO provides the least LV unloading and often requires a \"venting\" strategy (e.g., adding an Impella or IABP) to mitigate these effects.\n3.  C. TandemHeart: This device pumps blood from the left atrium (LA) to the femoral artery. By draining the LA, it significantly reduces LV preload, thereby unloading the LV. Its maximum flow is generally around 4.0 L/min.\n4.  B. Impella CP vs. E. Impella 5.5: Both are microaxial flow pumps placed across the aortic valve that actively aspirate blood from the LV and expel it into the ascending aorta. This mechanism directly reduces LV end-diastolic volume and pressure (uncoupling the LV from the arterial circulation), providing significant unloading (reduction in Pressure-Volume area).\n    *   Impella CP: Provides up to approximately 4.0–4.3 L/min of flow.\n    *   Impella 5.5: A surgically accepted (usually axillary) device that provides up to 5.5 L/min of flow.\n\nBecause the degree of LV unloading is proportional to the volume of blood removed from the ventricle and the reduction in wall tension, the device capable of the highest flow rate directly from the LV provides the greatest unloading. The Impella 5.5 offers higher flow capabilities than the Impella CP or TandemHeart.\n\nTherefore, among the choices provided, the Impella 5.5 provides the greatest degree of left ventricular unloading.\n\nThe answer is (E)"}]